bohlen.bsky.social
bohlen.bsky.social
@bohlen.bsky.social
Reposted by bohlen.bsky.social
Complete neutralizing antibody evasion by serodivergent non-mammalian AAVs enables gene therapy redosing @cp-cellrepmed.bsky.social
www.cell.com/cell-reports...
November 26, 2025 at 8:26 PM
Reposted by bohlen.bsky.social
Happy to see the field advance in leaps and bounds. Great news for terrible diseases!

When I postdoc’d developing lentivectors for gene therapy it was already used for severe combined immunodeficiency, but other applications seemed quite far away and the field was in the post-hype depression.

🧪
November 26, 2025 at 9:49 PM
Reposted by bohlen.bsky.social
Open Access UCL Research: Gene therapy for Parkinson's disease: trials and technical advances discovery.ucl.ac.uk/id/eprint/10...
Gene therapy for Parkinson's disease: trials and technical advances - UCL Discovery
UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
discovery.ucl.ac.uk
November 27, 2025 at 10:24 AM
Primates are absolutely critical for developing safe and effective gene therapies
November 26, 2025 at 7:22 PM
Reposted by bohlen.bsky.social
Signal or noise? > Viral Vectors-based Gene Therapy for Non-human Primates
Market - openPR.com >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #competitivemarketing
Viral Vectors-based Gene Therapy for Non-human Primates Market - openPR.com
Viral Vectors-based Gene Therapy for Non-human Primates Market  openPR.com
dlvr.it
November 26, 2025 at 12:59 PM
Reposted by bohlen.bsky.social
A top FDA regulator has announced that the agency plans to relax its strict rules for gene therapy development in an effort to fast-track gene therapies and boost investment in experimental treatments.
FDA clears way for faster personalized gene editing therapy
The FDA plans to unveil a new approval process for custom gene-editing, a move designed to unleash a wave of industry investment. Read on
financialpost.com
November 11, 2025 at 4:21 PM
Reposted by bohlen.bsky.social
Fear, monkeys, and institutional courage

When news broke of an explosion inside Harvard’s neurobiology building early Saturday morning, every scientist who works with monkeys felt it—an involuntary jolt, a spike of cortisol, the silent thought: what if it had been us? Neither animals nor people…
Fear, monkeys, and institutional courage
When news broke of an explosion inside Harvard’s neurobiology building early Saturday morning, every scientist who works with monkeys felt it—an involuntary jolt, a spike of cortisol, the silent thought: what if it had been us? Neither animals nor people were hurt, thankfully. It doesn’t appear to have been an attack. But it didn’t matter. For those of us who work with monkeys, the fear is always near the surface.
micheleabasso7.wordpress.com
November 6, 2025 at 7:21 PM
Reposted by bohlen.bsky.social
We desperately need new research tools to move the ball forward in Parkinson's. How about seeing dopamine in a new light? Enter 'far-red sensors' that unlock multiplex brain signals. Could a far-red dopamine sensor open the door to simultaneously watching multiple brain chemicals 'in action.'
November 7, 2025 at 12:53 PM
Reposted by bohlen.bsky.social
Single-cell, multi-region profiling of the macaque brain across the lifespan https://www.biorxiv.org/content/10.1101/2025.10.31.685880v1
November 1, 2025 at 10:15 AM
Reposted by bohlen.bsky.social
Dutch lawmakers have approved the phase-out of primate research at one of Europe’s biggest facilities. Neuroscientists are worried.

By Lauren Schenkman

#neuroskyence

www.thetransmitter.org/animal-model...
Nonhuman primate research to lose federal funding at major European facility
The Dutch Senate has ordered the Biomedical Primate Research Centre in the Netherlands to shift its funding away from primate experiments by 2030.
www.thetransmitter.org
October 30, 2025 at 7:24 PM
Reposted by bohlen.bsky.social
AAV Quantification: Towards Faster, More Scalable Analysis

https://www.byteseu.com/1496260/

Adeno-associated virus (AAV) is widely used in gene therapy as a vector to deliver genetic material into patient cells due to its specificity and low immunogenicity. Accurate AAV quantification and …
AAV Quantification: Towards Faster, More Scalable Analysis - Bytes Europe
Adeno-associated virus (AAV) is widely used in gene therapy as a vector to deliver genetic material into patient cells due to its specificity and low
www.byteseu.com
October 30, 2025 at 9:39 AM
Reposted by bohlen.bsky.social
Teenager who received Elevidys, Sarepta's Duchenne gene therapy, dies - STAT
Sarepta Therapeutics said that a young man died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy
October 16, 2025 at 2:15 AM
Reposted by bohlen.bsky.social
𝗔 𝗡𝗘𝗨𝗥𝗢𝗘𝗖𝗢𝗟𝗢𝗚𝗜𝗖𝗔𝗟 𝗣𝗘𝗥𝗦𝗣𝗘𝗖𝗧𝗜𝗩𝗘 𝗢𝗡 𝗧𝗛𝗘 𝗣𝗥𝗘𝗙𝗥𝗢𝗡𝗧𝗔𝗟 𝗖𝗢𝗥𝗧𝗘𝗫
By Mars and Passingham
"Understanding anthropoid foraging challenges may thus contribute to our understanding of human cognition"
Going to the top of the reading list!
doi.org/10.1016/j.ne...
#neuroskyence
October 11, 2025 at 4:31 PM
Reposted by bohlen.bsky.social
Signal or noise? > AviadoBio Looks to China for Eye-Based Gene Therapy in $413M
UgeneX Pact - BioSpace >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #biotech #pharmaceutical #healthcare
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact - BioSpace
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact  BioSpace
dlvr.it
October 10, 2025 at 1:00 PM
Reposted by bohlen.bsky.social
#ESGCT2025: A woman who was previously ineligible for @genethonfr.bsky.social's Crigler–Najjar syndrome gene therapy due to pre-existing immunity to AAV8 got the treatment after Hansa Bio's antibody-chopping drug imlifidase cleared the way. Read more in @endpts.com :

endpoints.news/new-study-su...
Person previously ineligible for gene therapy granted treatment after antibody-chopping drug clears the way
Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.
endpoints.news
October 10, 2025 at 7:16 PM
Reposted by bohlen.bsky.social
Signal or noise? > FDA awards RMAT designation to Dravet syndrome gene therapy
- Dravet Syndrome News >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #competitivemarketing
FDA awards RMAT designation to Dravet syndrome gene therapy - Dravet Syndrome News
FDA awards RMAT designation to Dravet syndrome gene therapy  Dravet Syndrome News
dlvr.it
October 7, 2025 at 8:00 PM
Reposted by bohlen.bsky.social
New preprint from our lab, led by our postdocs Dara Annett and Kate Morling in collaboration with Selwood Lab!

We developed a modified cyclosporine, BG147, which enhances lentivector gene therapy transduction, ex vivo in HSPC and in vivo in mouse photoreceptors, by degrading IFITM3. Check it out!
A modified cyclosporine enhances lentivector transduction ex vivo and in vivo by degrading IFITM3
Intrinsic innate immune barriers have evolved to suppress viral infection and can reduce effective gene delivery in gene therapy. We have developed BG147, a novel cyclosporine A analogue, optimised vi...
www.biorxiv.org
September 29, 2025 at 3:38 PM
Reposted by bohlen.bsky.social
Proud to share the Alzheimer’s Association invested $112.2M in research activities over the last year — our largest single-year commitment. From gene therapy to #BrainHealth to risk reduction to AI, we’re funding bold boundary-pushing ideas. alz.org/research

#ENDALZ
Alzheimer's & Dementia Research | Alzheimer's Association
Alzheimer's and dementia research – find the latest update on research funding, grants, clinical trials and global research news.
alz.org
September 19, 2025 at 6:40 PM
Reposted by bohlen.bsky.social
Children’s Healthcare of Atlanta recently performed Georgia’s first commercial gene therapy transplant for a genetic disease requiring lifelong blood transfusions. www.gpb.org/news/2025/09...
This teenager no longer needs lifelong blood transfusions thanks to gene transplant therapy
Children’s Healthcare of Atlanta recently performed Georgia’s first commercial gene therapy transplant for a genetic disease requiring lifelong blood transfusions.
www.gpb.org
September 15, 2025 at 12:44 PM
Reposted by bohlen.bsky.social
First Child Dosed in Gene Therapy Trial Dies.
www.medpagetoday.com/neurology/ge...
First Child Dosed in Gene Therapy Trial Dies
Investigational agent aimed to treat rare gene-related encephalopathy
www.medpagetoday.com
September 14, 2025 at 3:16 AM
Reposted by bohlen.bsky.social
Feeling a bit tearful at the moment. A gene therapy for RRP, the airway disease I've had for 25 years now, has been developed and is now approved. For those of us who've had anything between 50-500 throat operations, this is an absolute life changer!
biotechhealthx.com/biotech-news...
Precigen (PGEN) Makes History: FDA Approves First-Ever Therapy Targeting Root Cause of RRP
Precigen’s PAPZIMEOS therapy is transforming the lives of adults with recurrent respiratory papillomatosis, eliminating endless surgeries.
biotechhealthx.com
August 26, 2025 at 6:45 PM
Reposted by bohlen.bsky.social
NCBN Trending: Gene therapy startup Kriya Therapeutics gets $313M https://zpr.io/V27wP4Znjfxt
August 17, 2025 at 3:31 AM